Md Yuzaiful Md Yusof Yuz6Yusof
3 years 4 months ago
Delighted to be reporting for @RheumNow LIVE from Milan 🇮🇹 #EULAR2023 alongside my esteemed colleagues @drdavidliew @Janetbirdope @jeffsparks @synovialjoints @AurelieRheumo @bella_mehta 🙌🏻 Do follow us for Congress coverage 😃 https://t.co/tmD4vVWnQk
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 4 months ago
#EULAR2023 Please find my first article on Congress Preview of Promising New Therapies in #lupus #SLE @RheumNow
https://t.co/SFvhsP8QWO https://t.co/m5UwBGCXFB
Aurelie Najm AurelieRheumo
3 years 4 months ago
A full house for the #EULAR2023 Opening session @eular_org setting the tone for an exciting few days to come!
@RheumNow https://t.co/bZSIL78mU6
Dr. John Cush RheumNow
3 years 4 months ago
Tuesday Night Rheumatology: POD 4: Rheumatoid Arthritis: Decisive Therapeutics https://t.co/GzLE2XLe1q
Dr. John Cush RheumNow
3 years 4 months ago
Watch: A Family History of Ankylosing Spondylitis
https://t.co/3U7DG8P52c https://t.co/lxial62ujS
Dr. John Cush RheumNow
3 years 4 months ago
Watch: Evaluation of Sacroiliac Joint
RheumNow Live: Prof. Denis Poddubnyy, Charité University Hospital, Berlin
https://t.co/vH866d5sy6 https://t.co/zSMMBedyoG
EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR 2023.
Dr. John Cush RheumNow
3 years 4 months ago
Prevalence of PsA, Spondyloarthritis and Rheumatoid Arthritis in Norway
Recent reports have suggested a rising and unrecognized number of patients with PsA and axSpA compared to RA. This has implications on diagnosis and population care.
https://t.co/D0SvKP2MIa https://t.co/Gjh0oSZ5S2
Treatment of osteoarthritis is a major unmet need, as there are few therapies effective at pain control and no options for disease modification; yet a new trial in Annals of Internal Medicine suggest that chronic low dose colchicine may alter disease progression and lower the risk of of total knee and total hip replacements.
Dr. John Cush RheumNow
3 years 4 months ago
Lupus Landmark Study to Accelerate Personalized Lupus Treatments
The Lupus Landmark Study, the largest study of its kind in lupus, will prospectively recruit and longitudinally follow 3,500 adults diagnosed with SLE.
https://t.co/nzCqk8AxK6 https://t.co/IS9OS08CmH
Dr. John Cush RheumNow
3 years 4 months ago
Tonight! The final Tuesday Night Rheumatology of May.
This webinar will feature highlights from these lectures followed by live audience Q & A:
Methotrexate Use: 50 Yr. Perspective
Myths vs Reality in RA
Biosimilars - Back on the Agenda
https://t.co/NRAtlQ96e3 https://t.co/j6WVyFacUc
Dr. John Cush RheumNow
3 years 4 months ago
TAS5315, BTK inhibitor, studied in 91 MTX refractory RA pts. Wk 12 ACR20 resp was 79% on TAS5315 vs 60% PBO (p=0.053); ACR50 (33 vs 13%) not signif. Adverse event equal betw grps, but 9 pts had bleeding on TAS5315 https://t.co/XYS0XRMJar https://t.co/ntGtahFf4T
Dr. John Cush RheumNow
3 years 4 months ago
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/8BMTmJqhPq https://t.co/BOMsk38KB2
